Form D · Pharmaceuticals
Primrose Therapeutics, Inc.
New York, NY · CIK 0001499169
Offering snapshot reported Aug 13, 2010 · SEC filing
- Reported sold
- $753K Offering amount: $1.5M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 30, 2010 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 13, 2010 | Initial | $752,550 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-146420
Source: Form D, filed Aug 13, 2010. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jeffrey S. Edelman | Director, Executive |
| Mark Kessel | Director, Executive |
| Zachary S. Sharon | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
875 Third Avenue 3 Rd Floor
New York, NY, 10022
New York, NY, 10022